Our Values
Innovation, Collaboration, and Hope
Outsmarting cancer, together
Omico is a nationwide network of research and treatment centres that facilitates, supports and promotes clinical trials in genomic cancer medicine. Central to this is the use of molecular screening for the prevention and treatment of cancer.
Our Mission
Recent News
Pancreatic cancer program
Cancer Institute NSW has awarded a Translational Program Grant to an impressive team of experienced laboratory and clinical researchers in pancreas cancer, coordinated by Chief Investigator Professor David Goldstein. The team is seeking to develop better targeted treatment options for pancreatic cancer – and ultimately, improve outcomes for people affected.
2020 Masterclass Publications and webinar recordings
View the "Demystifying the Molecular Tumour Board" Masterclass publication and webinar recordings
ASPiRATION study - first patient enrolled
The first patient has been enrolled into the ‘ASPiRATION’ Study. The study is looking at the impact and value of comprehensive genomic profiling (CGP), precision medicine and personalised healthcare (PHC) in newly diagnosed metastatic, non-squamous, non-small cell lung cancer patients.